• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

获得性血友病A患者中的交叉反应性抗猪因子VIII抑制剂。

Cross-reacting antiporcine factor VIII inhibitors in patients with acquired hemophilia A.

作者信息

Stephen Maddie, Elbaz Carolyne, Hanif Hina, Pavenski Katerina, Teitel Jerry, Sholzberg Michelle

机构信息

Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada.

Department of Medicine, Division of Hematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

出版信息

Res Pract Thromb Haemost. 2024 Aug 22;8(6):102553. doi: 10.1016/j.rpth.2024.102553. eCollection 2024 Aug.

DOI:10.1016/j.rpth.2024.102553
PMID:39309227
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11416523/
Abstract

•Recombinant porcine factor VIII (rpFVIII) is a hemostatic treatment for bleeding in acquired hemophilia A.•The efficacy of rpFVIII can be negatively affected by cross-reacting anti-human FVIII antibodies.•In this cohort, 52% of patients with acquired hemophilia A had baseline cross-reacting antibodies.•Cross-reacting antibodies were associated with decreased FVIII activity levels post-rpFVIII infusion.

摘要

•重组猪因子VIII（rpFVIII）是治疗获得性血友病A出血的一种止血疗法。

•rpFVIII的疗效可能会受到交叉反应性抗人FVIII抗体的负面影响。

•在该队列中，52%的获得性血友病A患者有基线交叉反应性抗体。

•交叉反应性抗体与rpFVIII输注后FVIII活性水平降低有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdbc/11416523/4b3cec61182e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdbc/11416523/4b3cec61182e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdbc/11416523/4b3cec61182e/gr1.jpg

相似文献

1
Cross-reacting antiporcine factor VIII inhibitors in patients with acquired hemophilia A.获得性血友病A患者中的交叉反应性抗猪因子VIII抑制剂。
Res Pract Thromb Haemost. 2024 Aug 22;8(6):102553. doi: 10.1016/j.rpth.2024.102553. eCollection 2024 Aug.
2
Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.获得性血友病A中针对重组猪因子VIII的交叉反应性抑制剂：来自GTH-AH 01/2010研究的数据。
J Thromb Haemost. 2020 Jan;18(1):36-43. doi: 10.1111/jth.14618. Epub 2019 Sep 12.
3
Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors.重组猪因子 VIII 治疗因子 VIII 抑制剂患者的短期疗效。
Haemophilia. 2020 Jul;26(4):601-606. doi: 10.1111/hae.14014. Epub 2020 Apr 27.
4
Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A.获得性 A 型血友病患者中交叉反应性重组猪 FVIII 抑制剂。
Haemophilia. 2020 Nov;26(6):1181-1186. doi: 10.1111/hae.14162. Epub 2020 Sep 30.
5
Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A.重组抗血友病猪序列因子VIII用于获得性甲型血友病成人患者的综述。
Ther Adv Hematol. 2017 Sep;8(9):263-272. doi: 10.1177/2040620717720861. Epub 2017 Aug 3.
6
Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII.重组猪因子VIII对抗因子VIII抑制剂的中和作用。
J Thromb Haemost. 2006 Oct;4(10):2223-9. doi: 10.1111/j.1538-7836.2006.02135.x. Epub 2006 Jul 20.
7
Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review.使用重组凝血因子IX（苏苏妥凝血因子α）治疗获得性血友病的手术及预防：病例系列与文献综述
J Clin Med. 2023 Jul 10;12(14):4590. doi: 10.3390/jcm12144590.
8
Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A.重组猪因子 VIII 在日本获得性血友病 A 患者中的疗效和安全性。
Int J Hematol. 2024 Oct;120(4):482-491. doi: 10.1007/s12185-024-03823-y. Epub 2024 Aug 19.
9
Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort.用于治疗获得性血友病 A 出血的重组猪 FVIII：来自单中心、18 例患者队列的研究结果。
Blood Adv. 2020 Dec 22;4(24):6240-6249. doi: 10.1182/bloodadvances.2020002977.
10
Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.实验室凝血检测与重组猪因子 VIII：英国血友病中心医生组织指南。
Haemophilia. 2022 May;28(3):515-519. doi: 10.1111/hae.14536. Epub 2022 Mar 13.

本文引用的文献

1
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021.重组猪源凝血因子VIII：过去的经验教训及在2021年伴抑制物的甲型血友病管理中的地位
Res Pract Thromb Haemost. 2021 Nov 21;5(8):e12631. doi: 10.1002/rth2.12631. eCollection 2021 Dec.
2
Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.获得性血友病A中针对重组猪因子VIII的交叉反应性抑制剂：来自GTH-AH 01/2010研究的数据。
J Thromb Haemost. 2020 Jan;18(1):36-43. doi: 10.1111/jth.14618. Epub 2019 Sep 12.
3
Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients.
重组猪序列因子VIII（rpFVIII）用于获得性血友病A：7例患者使用该药的实际临床经验
Haemophilia. 2017 Jan;23(1):25-32. doi: 10.1111/hae.13040. Epub 2016 Aug 10.
4
Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.重组猪序列抗血友病因子VIII（OBI-1）在获得性血友病A患者中的疗效和安全性。
Haemophilia. 2015 Mar;21(2):162-170. doi: 10.1111/hae.12627. Epub 2015 Jan 27.
5
Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C).猪源凝血因子VIII（HYATE:C）治疗后的血小板活化与高凝状态。
Am J Hematol. 2002 Mar;69(3):192-9. doi: 10.1002/ajh.10057.
6
Investigation of porcine parvovirus among persons with hemophilia receiving Hyate:C porcine factor VIII concentrate.
Transfusion. 2000 Jun;40(6):708-11. doi: 10.1046/j.1537-2995.2000.40060708.x.
7
The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.用于检测因子VIII:C抑制剂的贝塞斯达检测法的奈梅亨改良法：提高了特异性和可靠性。
Thromb Haemost. 1995 Feb;73(2):247-51.